ZYME Zymeworks Inc: Enterprise Value-to-Revenue Multiple

Public company logo of zymeworks.com (ZYME)

Zymeworks Inc. business is completely independent of economic downturns, as confirmed by the current EV/Sales value. The 9092.98 metric determines this level of market valuation. The reliability of sterile antibody supply chains guarantees therapy safety, while the development of a multi-target platform through partnerships minimizes financial risks and competitive pressure during clinical trial stages.

Company Value to Revenue: Zymeworks Inc (ZYME) for 11/23/2025 - 11/20/2026

zymeworks.com - analytical breakdowns and key metrics (ZYME)

- share price and consensus valuation forecast:
Initial company analysis:Zymeworks Inc. ZYME
Product sample of Zymeworks Inc.

Investors use this criterion to determine the fair value of a business during the initial screening of assets. The metric compares the total enterprise value, including debt and cash, with the volume of generated revenue. This is critical for Zymeworks Inc. (ZYME), as the high cost of antibody development amid competition from CAR-T therapy necessitates strict control over overpayment. By analyzing the EV/Sales multiple history, one can assess the risk of purchasing an overvalued asset during a period of expensive capital.

Competitor analysis for Zymeworks Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|TNGX - Enterprise Value-to-Sales Ratio|Company Value to Revenue IOVA (Iovance)|Enterprise Value-to-Revenue Coefficient IMTX|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP